Key Takeaways RDY reported Q3 earnings of $0.16/ADS, matching estimates, while revenues rose 4.4% but missed expectations.RDY's global generics grew 7% YoY, but North America revenues fell 12% on lower lenalidomide sales.RDY's gross margin fell to 53.6% on price erosion, weaker mix and one-time provisions from new Labor Codes.Dr. Reddy's Laboratories Limited (RDY) reported third-quarter fiscal 2026 earnings of 16 cents per American Depositary Share (ADS), which matched the Zacks Consensus Estimate. The comp ...